PrRPR Reporter Assay System (human)

This is an all-inclusive cell-based luciferase reporter assay kit targeting the the Human Prolactin-Releasing Peptide Receptor (PrRPR / GPR10). INDIGO's PrRPR reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the PrRPR. In addition to PrRPR Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against PrRPR. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture. Features Clear, Reproducible Results All-Inclusive Assay Systems Exceptional Cell Viability Post-Thaw Consistent Results Lot to Lot Product Specifications Target Type GPCR Species Human Receptor Form Hybrid Assay Mode Kit Components PrRPR Reporter Cells Cell Recovery Medium (CRM) Compound Screening Medium (CSM) PrRP-31, 500 µM (in DMSO) Detection Substrate Detection Buffer 96-well, collagen-coated assay plate (white, sterile, cell-culture ready) Shelf Life 6 months Shipping Requirements Dry Ice Storage temperature -80C. Target Background Prolactin-releasing peptide receptor (PrRPR, a.k.a. GPR10) is a member of the class A peptide-GPCR family that regulates diverse physiological functions upon activation by Prolactin-releasing peptide (PrRP). In humans, PrRP has two active forms, PrRP-31 and PrRP-20 which are the only known endogenous ligands for PrRPR. Evidence increasingly shows the involvement of PrRPR signaling in the regulation of food intake, energy balance, stress response, hormonal activity and circadian rhythms and sleep. As such PrRPR/GPR10 may be a suitable target for the development of therapeutics that manage and treat obesity.